Progress with amendments to the EU variations regulation and guidelines

Last updated: 22 September 2025 To view updates, click on the ‘+’ sign below. This post provides information on the ongoing changes to the EU the variation Regulation (EC) No 1234/2008 and guidelines. The commission delegated regulation Timeline of events leading…

Read MoreProgress with amendments to the EU variations regulation and guidelines

New FDA process to facilitate approval of drugs to treat rare diseases in very small patient populations

On 3 September 2025, FDA’s CDER and CBER proposed a new process under Rare Disease Evidence Principles (RDEP) to facilitate the approval of drugs to treat rare diseases with very small patient populations with significant unmet medical need and with…

Read MoreNew FDA process to facilitate approval of drugs to treat rare diseases in very small patient populations

MHRA guidance on medicines MAH submission of nitrosamine risk evaluation, risk assessment and confirmatory testing updated

This guidance has been updated to include sections on the following: Lifecycle management MAHs are reminded of their responsibilities to ensure the quality, safety and efficacy of their medicines and are expected to continue to review and re-visit the outcome…

Read MoreMHRA guidance on medicines MAH submission of nitrosamine risk evaluation, risk assessment and confirmatory testing updated

Swissmedic updates to guidances on time limits for authorisation applications, formal requirements and product information

In this post, information is provided on the following updated guidance documents: Changes to the guidance document Time limits for authorisation applications Swissmedic is shortening the procedural time limits for applications for new authorisation of medicinal products with known active…

Read MoreSwissmedic updates to guidances on time limits for authorisation applications, formal requirements and product information

European Court cases involving Supplementary Protection Certificates

Last updated: 20 August 2025 To view updates, click on the ‘+’ sign below. The table below is an attempt to present some court cases involving Supplementary Protection Certificates. You can read more about Supplementary Protection Certificates (SPCs) and Supplementary…

Read MoreEuropean Court cases involving Supplementary Protection Certificates

EMA feedback to the EC request to evaluate the feasibility of alternatives to replace TiO2 in medicinal products and its possible impact on the availability of medicines

Last updated: 8 August 2025 To view updates, click on the ‘+’ sign below: The information for this post has been obtained from the report (of 1 April 2024) with the title above, published on 6 August 2025. Whilst the…

Read MoreEMA feedback to the EC request to evaluate the feasibility of alternatives to replace TiO2 in medicinal products and its possible impact on the availability of medicines